<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-08-11">August 11, 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Michael</forename><surname>Schmitt</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Universitätsklinikum Heidelberg</orgName>
								<orgName type="institution" key="instit2">Medizinische Klinik V</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Angela</forename><forename type="middle">G</forename><surname>Hückelhoven</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Universitätsklinikum Heidelberg</orgName>
								<orgName type="institution" key="instit2">Medizinische Klinik V</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Hundemer</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Universitätsklinikum Heidelberg</orgName>
								<orgName type="institution" key="instit2">Medizinische Klinik V</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anita</forename><surname>Schmitt</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Susanne</forename><surname>Lipp</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Universitätsklinikum Heidelberg</orgName>
								<orgName type="institution" key="instit2">Medizinische Klinik V</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martina</forename><surname>Emde</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Universitätsklinikum Heidelberg</orgName>
								<orgName type="institution" key="instit2">Medizinische Klinik V</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hans</forename><surname>Salwender</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Universitätsklinikum Heidelberg</orgName>
								<orgName type="institution" key="instit2">Medizinische Klinik V</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Internal Medicine II</orgName>
								<orgName type="institution">Asklepios Klinik Altona</orgName>
								<address>
									<settlement>Hamburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mathias</forename><surname>Hänel</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="institution">Klinikum Chemnitz GmbH</orgName>
								<address>
									<settlement>Chemnitz</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Katja</forename><surname>Weisel</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Hematology, Oncology and Immunology</orgName>
								<orgName type="institution">University of Tübingen</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Uta</forename><surname>Bertsch</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Universitätsklinikum Heidelberg</orgName>
								<orgName type="institution" key="instit2">Medizinische Klinik V</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><surname>Dürig</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution">University Hospital Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anthony</forename><forename type="middle">D</forename><surname>Ho</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Universitätsklinikum Heidelberg</orgName>
								<orgName type="institution" key="instit2">Medizinische Klinik V</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Igor</forename><forename type="middle">Wolfgang</forename><surname>Blau</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Medical Clinic III Hematology and Oncology</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hartmut</forename><surname>Goldschmidt</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Universitätsklinikum Heidelberg</orgName>
								<orgName type="institution" key="instit2">Medizinische Klinik V</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="institution">Nationales Centrum für Tumorerkrankungen</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anja</forename><surname>Seckinger</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Universitätsklinikum Heidelberg</orgName>
								<orgName type="institution" key="instit2">Medizinische Klinik V</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Dirk</forename><surname>Hose</surname></persName>
							<email>dirk.hose@med.uni-heidelberg.de</email>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Universitätsklinikum Heidelberg</orgName>
								<orgName type="institution" key="instit2">Medizinische Klinik V</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-08-11">August 11, 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">11D44C630921676475888CD5968B3756</idno>
					<note type="submission">Received: May 20, 2016 Accepted: July 13, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:49+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>tumor associated antigens</term>
					<term>T cells</term>
					<term>immunogenicity</term>
					<term>multiple myeloma</term>
					<term>RNA-sequencing</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Raising T-cell response against antigens either expressed on normal and malignant plasma cells (e.g.</s><s>HM1.24) or aberrantly on myeloma cells only (e.g.</s><s>cancer testis antigens, CTA) by vaccination is a potential treatment approach for multiple myeloma.</s><s>Results: Expression by GEP is found for HM1.24 in all, HMMR in 318/458 (69.4%),</s><s>MAGE-A3 in 209/458 (45.6%),</s><s>NY-ESO-1/2 in 40/458 (8.7%), and WT-1 in 4/458 (0.8%) of samples with the pattern being confirmed by RNA-sequencing.</s><s>T-cell-activation is found in 9/26 (34.6%) of patient samples, i.e. against HM1.24 (4/24), RHAMM-R3 (3/26), RHAMM1-8 (2/14), WT-1 (1/11), NY-ESO-1/2 (1/9), and MAGE-A3 (2/8).</s><s>In 7/19 T-cell activation responses, myeloma cells lack respective antigen-expression.</s><s>Expression of MAGE-A3, HMMR and NY-ESO-1/2 is associated with adverse survival.</s><s>Experimental design: We assessed expression of HM1.24 and the CTAs MAGE-A3, NY-ESO-1/2, WT-1 and HMMR in CD138-purified myeloma cell samples of previously untreated myeloma patients in the GMMG-MM5 multicenter-trial by gene expression profiling (GEP; n = 458) and RNA-sequencing (n = 152) as potential population regarding vaccination trials.</s><s>We then validated the feasibility to generate T-cell responses (n = 72) against these antigens by IFN-γ EliSpot-assay (n = 26) related to antigen expression (n = 22).</s><s>Lastly, we assessed survival impact of antigen expression in an independent cohort of 247 patients treated by high-dose therapy and autologous stem cell transplantation.</s><s>Conclusions: As T-cell responses can only be raised in a subfraction of patients despite antigen expression, and the number of responses increases with more antigens used, vaccination strategies should assess patients' antigen expression and use a "cocktail" of peptide vaccines.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Multiple myeloma is characterized by the accumulation of clonal plasma cells in the bone marrow and associated clinical signs and symptoms, especially those related to the displacement of normal hematopoiesis, generation of osteolytic bone disease, and production of a monoclonal protein <ref type="bibr" target="#b0">[1]</ref>.</s><s>One of the most prominent effects thereof is the induction of immunosuppression visible in dysfunctional dendritic cells (DC) and diminished T-cell activation <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref>.</s><s>In turn, immunotherapeutic approaches to eliminate myeloma cells by fostering host immunity are in development.</s><s>Most advanced is the recruitment of innate immunity to kill myeloma cells by monoclonal antibodies targeting antigens either aberrantly expressed on myeloma cells (e.g.</s><s>SLAMF7 -elotuzumab <ref type="bibr" target="#b4">[5]</ref>) or expressed on both, normal as well as malignant plasma cells (e.g.</s><s>CD38 -daratumumab <ref type="bibr" target="#b5">[6]</ref>, isatuximab <ref type="bibr" target="#b6">[7]</ref>).</s><s>A different approach is (re)directing T-cells towards myeloma cell killing.</s><s>This can be achieved via T-cell genetic engineering with chimeric antigen receptors or recombinant T-cell receptor, both requiring ex vivo engineering and expansion of patient specific T-cells <ref type="bibr" target="#b8">[8]</ref><ref type="bibr" target="#b10">[9]</ref><ref type="bibr" target="#b11">[10]</ref><ref type="bibr" target="#b12">[11]</ref>, as well as T-cell bispecific antibodies that simultaneously bind a surface target on tumor cells and an associated T-cell receptor chain present on T-cells thereby inducing potent T-cell mediated killing of cells carrying the target <ref type="bibr" target="#b13">[12,</ref><ref type="bibr" target="#b14">13]</ref>.</s><s>A further -and potentially even prophylactic -approach is the development of cancer vaccines generating myelomaspecific immunity selectively targeting malignant cellswith limited toxicity to normal tissues <ref type="bibr" target="#b15">[14]</ref><ref type="bibr" target="#b16">[15]</ref><ref type="bibr" target="#b17">[16]</ref>.</s><s>Potential targets comprise those constitutively expressed on normal as well as on malignant plasma cells (e.g.</s><s>HM1.24) <ref type="bibr" target="#b18">[17]</ref><ref type="bibr" target="#b19">[18]</ref><ref type="bibr" target="#b20">[19]</ref>, or those expressed on malignant cells but not their normal counterpart, e.g.</s><s>cancer testis antigens (CTA).</s><s>In multiple myeloma, several CTAs have been described by others and us, including MAGE-A3 (melanomaassociated antigen 3) <ref type="bibr" target="#b21">[20]</ref><ref type="bibr" target="#b22">[21]</ref><ref type="bibr" target="#b23">[22]</ref><ref type="bibr" target="#b24">[23]</ref>, NY-ESO-1 (New York esophageal-1) <ref type="bibr" target="#b25">[24]</ref><ref type="bibr" target="#b26">[25]</ref><ref type="bibr" target="#b28">[26]</ref><ref type="bibr" target="#b29">[27]</ref>, WT-1 (Wilms' tumor gene 1) <ref type="bibr" target="#b30">[28]</ref><ref type="bibr" target="#b31">[29]</ref><ref type="bibr" target="#b32">[30]</ref>, and RHAMM/HMMR (receptor of hyaluronic acid mediated motility) <ref type="bibr" target="#b33">[31]</ref><ref type="bibr" target="#b34">[32]</ref><ref type="bibr" target="#b35">[33]</ref>.</s><s>Of these, MAGE-A3, NY-ESO-1/2, and WT-1 are not expressed in normal bone marrow plasma cells but aberrantly in malignant plasma cells <ref type="bibr" target="#b36">[34,</ref><ref type="bibr" target="#b37">35]</ref>.</s><s>HMMR <ref type="bibr" target="#b38">[36]</ref>, MAGE-A3, and NY-ESO-1 <ref type="bibr" target="#b36">[34]</ref> are associated with adverse survival.</s></p><p><s>In this article, we address patients treated by up-front high-dose therapy and autologous stem cell transplantation included in the GMMG-MM5 trial as potential population regarding vaccination trials (n = 604).</s><s>We first assessed expression of HM1.24 and the CTAs HMMR, NY-ESO-1/2, MAGE-A3 and WT-1 by using DNA-microarrays (n = 458) and validation by RNA-sequencing (n = 152).</s><s>We next assessed a representative cohort of 72 consecutive patients regarding the possibility to raise T-cell specific answers.</s><s>Subsequently, the interrelation of antigen expression and generation of T-cell responses was addressed.</s><s>Lastly, we used a comparable cohort of 247 previously untreated myeloma patients with long-term follow up to investigate the impact of expression of the respective antigens on survival.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Antigen-expression</head><p><s>Antigen expression assessed by DNA-microarrays is depicted in the following for the GMMG-MM5 cohort as well as the part of this cohort validated by RNAsequencing [in brackets, for gene expression profiling].</s><s>HM1.</s><s><ref type="bibr" target="#b25">24</ref>   <ref type="figure" target="#fig_0">S1</ref>).</s></p><p><s>RNA-sequencing validates expression showing an identical expression pattern for the observed antigens with normalized read counts above one being observed for HM1.24 in all, HMMR in 144/152 (94.7%),</s><s>MAGE-A3 in 77/152 (50.7%),</s><s>NY-ESO-1/2 in 20/152 (13.2%), and WT-1 in 5/152 (3.3%) of corresponding samples (Figure <ref type="figure" target="#fig_0">1</ref>, Table <ref type="table" target="#tab_0">1</ref>).</s><s>GEP and RNA-sequencing show an overall correlation (Pearson) for HM1.24 (r 2 = .68),</s><s>HMMR (r 2 = 72), MAGE-A3 (r 2 = .74),</s><s>NY-ESO-1/2 (r 2 = .72),</s><s>and WT-1 (r 2 = .18),</s><s>Supplementary Figure <ref type="figure" target="#fig_1">S2</ref>.</s></p><p><s>For individual patients, the mean correlation between GEP and RNA-seq for the five investigated genes is tight, i.e. a median correlation coefficient (Pearson) of 0.95 (see also Supplementary Figure <ref type="figure" target="#fig_1">S2 and discussion</ref>).</s><s>For expression data regarding the functional validation cohort, see Table <ref type="table" target="#tab_0">1</ref> and Supplementary Figure <ref type="figure" target="#fig_0">S1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Functional T-cell response</head><p><s>Regarding patients, as for any vaccination approach using HLA-A2-restricted peptides, applicability is limited to about half of patients, i.e. 53.6% (37/69) in our cohort (Supplementary Figure <ref type="figure" target="#fig_5">S3</ref>).</s><s>In these, a T-cell response could be raised in 9/26 (34.6%) patients, of which 5/26 (19.2%) and 4/26 (15.4%) were classified as strong and weak, respectively.</s><s>Regarding tests performed, a response was found in 19/80 tests (23.8%), i.e. 6/12 (50%) against HM1.24, 4/26 (15.4%) against HMMR3, 2/14 (14.3%) against HMMR1-8, 4/11 (36.4%) against WT-1, 1/9 (11.1%) against NY-ESO-1, and 2/8 (25%) against MAGE-A3.</s><s>A strong response was found in a total of 10/80 (12.5%), i.e. 4/12 (25%) against HM1.24, 3/26(11.5%)</s><s>against HMMR3, 2/14 (14.3%) against HMMR1-8, 1/11 (9.1%) against WT-1, as well as none of 9 and 8, respectively, www.impactjournals.com/oncotarget</s><s>against NY-ESO-1 or MAGE-A3 (Table <ref type="table" target="#tab_4">2</ref>).</s><s>IFNγ secretion of CTA-specific CD8 + T-cells from the bone marrow of exemplary patients is shown in Figure <ref type="figure" target="#fig_1">2</ref>.</s></p><p><s>Of 10 observed strong T-cell responses in 22 patients with GEP-data available, 7 were observed with the respective antigen indicated as "expressed" vs. 3 in case of an "absent" signal (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Related to all tested antigens, responses were found in 12/35 tests where the respective antigen was expressed, vs. 7/26 in which this was not the case, (P = n.s.).</s><s>In sample 4 showing a strong T-cell specific response, complete absence of WT-1 expression was confirmed using RNA-sequencing (0 reads).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Impact on survival</head><p><s>We next investigated an independent cohort of 247 patients treated by high-dose therapy and autologous stem cell transplantation with comparable expression pattern regarding the association of CTA expression with eventfree and overall survival.</s><s>Of the investigated antigens, HMMR, MAGE-A3, and NY-ESO-1/2 are significantly associated with inferior event-free and overall survival (Figure <ref type="figure" target="#fig_2">3</ref>).</s><s>No association with survival is found for the constitutively expressed HM1.24 as well as for WT-1 (data not shown).</s><s>For the correlation of CTA expression and tumor mass (i.e.</s><s>ISS stage), gene expression-</s></p><formula xml:id="formula_0">+ p - n n a - + p - n a - + a - 14 - - - n - - - - - - - - - - - - 15 - - - n - - - - - - - - - - - - 16 - p - n - p - - p - - a - - a - 17 n - - n n - - n - - n - - n - -<label>18</label></formula><formula xml:id="formula_1">21 n - - n n - - - - - - - - n - - 22 - p - n n p - - a - - a - - a - 23 - p - n - p - - p - - a - - a - 24 n p - n n p - - p - - a - - a - 25 - p - ++ - a - - p - - a - - a - 26 - p - n - p - - p - - a - - a -</formula><p><s>GEP, gene expression profiling, "absence" (a) and "presence" (p) of gene expression assessed by "presence-absence calls with negative-strand matching probe-sets" (PANP) algorithm.</s><s>RNA-seq, RNA-sequencing, respective quantitative values depicted as normalized count rates.</s><s>Response: light green (+) indicates specific T-cell response against the respective antigen defined as ≥ 2-fold increased number of positive ELISPOTs compared to control, dark green (++) strong response defined as ≥ 3-fold increased number of positive ELISPOTs compared to control.</s><s>Orange, response can be raised although the antigen is not expressed.</s><s>Light gray, no response (n).</s><s>White, not available.</s><s><ref type="table" target="#tab_1">S1</ref>).</s><s>The strong prognostic impact of HMMR can be explained by gene expression being highly associated with proliferation of malignant plasma cells (Figure <ref type="figure" target="#fig_3">4</ref>).</s><s>The gene is likewise part of our gene expression-based risk score, i.e.</s><s>Rs-score <ref type="bibr" target="#b39">[37]</ref>.</s><s>Secondly, we assessed the number of aberrantly expressed CTAs finding an association of the number of expressed CTAs &gt; 1 and adverse event-free survival, but not overall survival (Jonckheere-Terpstra trend-test, P &lt; .001;</s><s>Supplementary Table <ref type="table" target="#tab_4">S2</ref>).</s><s>Again, the likely explanation of this is the association of the number of CTAs and risk-/proliferation-scores (Figure <ref type="figure" target="#fig_4">5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION HM1.24 and CTAs as vaccinational targets in symptomatic myeloma</head><p><s>For clinical applicability in terms of potential vaccination trials, several conclusions can be drawn from our trial population based study.</s><s>As for any vaccination approach using HLA-A2-restricted peptides, applicability is limited to about half of patients, i.e. 53.6% (37/69) in our cohort.</s><s>In these patients, T-cell responses could be raised in 9/26 (34.6%) patients, leading to a patient population based rate of 18.4%.</s><s>Even if the respective antigen was expressed ("mimicking" vaccination), e.g.</s><s>HM1.24 (in all), HMMR (in 69.4% of samples), only in about half of cases a T-cell response could be raised (Tables <ref type="table" target="#tab_4">1, 2</ref>, Figure <ref type="figure" target="#fig_0">1</ref>, Supplementary Figure <ref type="figure" target="#fig_0">S1</ref>).</s><s>With increasing numbers of CTAs used, T-cell responses become more likely (Table <ref type="table" target="#tab_4">2</ref>).</s><s>Both findings suggest the use of a polyvalent vaccine, i.e. a "cocktail" of peptides as a vaccines, as previously envisioned by us based on CTA-expression alone <ref type="bibr" target="#b36">[34]</ref>.</s><s>Of the investigated antigens, HM1.24 (100%), HMMR (64.9%), and MAGE-A3 (45.6%) are frequently expressed targets.</s><s>As is NY-ESO-1/2, with the caveat of delineation which of the three genes actually underlies the observed expression.</s><s>Regarding GEP, this is due to the interrogation of all three genes (CTAG1A, CTAG1B, CTAG2) by probe set 210546_x_at, and CTAG1A as well as CTAG1B alongside a third and fourth probe set (2173339_x_at and 211674_x_at).</s><s>Regarding RNA-sequencing, a potential difficulty is the observed high sequence homology in genes coding for NY-ESO-1/2, in turn leading to reads in RNA-sequencing simultaneously mapping to different genes, and, consecutively, are discarded due to "low quality" depending on the aligner and counting algorithm used.</s><s>This potentially also explains the high variability in reported frequencies of NY-ESO-1 expression <ref type="bibr" target="#b25">[24,</ref><ref type="bibr" target="#b40">38,</ref><ref type="bibr" target="#b41">39]</ref>.</s><s>The reported frequencies here are however cell precursors, i.e. memory B-cells (MBC) and in vitro generated polyclonal plasmablastic cells (PPC), as well as normal bone marrow plasma cells (BMPC), malignant plasma cells from patients with newly-diagnosed multiple myeloma (MM), and human myeloma cell lines (HMCL).</s><s>Left panel shows gene expression profiling using DNA-microarrays with black numbers depicting the number of patient samples expressing the respective gene according to the PANP-algorithm, gray number the one that showed no expression.</s><s>Right panel shows gene expression profiling using RNA-sequencing with numbers depicting the total number of samples assessed.</s><s>Significant difference is depicted by one asterisk (*) for a level of P &lt; 0.05, two asterisks (**) for a level of P &lt; 0.01, and three (***) for P &lt; 0.001.</s><s>Shown is a summary of the number of patients that recognize the different CTA-specific epitopes, respectively.</s><s>The Empirical Rule applied here is 2 × SFU more than negative control.</s><s>The percentage of the positive results in the groups of patients was calculated.  in agreement with detected frequencies of NY-ESO-1 expression previously found by us using qRT-PCR <ref type="bibr" target="#b1">[2]</ref>.</s><s>Expression of CTAs is associated with adverse survival patients in treated by high-dose therapy and autologous stem cell transplantation (Figure <ref type="figure" target="#fig_2">3</ref>), confirming earlier reports by others and us <ref type="bibr" target="#b36">[34,</ref><ref type="bibr" target="#b38">36]</ref>.</s><s>This could be of special interest if, as e.g.</s><s>shown for AML by us <ref type="bibr" target="#b33">[31]</ref>, likewise myeloma patients with HMMR-T-cell-responses would have better survival, and thus respective approaches especially impact on patients with more adverse risk.</s><s>A further conclusion from the expression pattern of CTAs is that these would need to be measured within a clinical vaccination trial -raised T-cell responses would evidently only be useful if the target antigen is (or will be) expressed on the respective malignant plasma cells.</s><s>As demonstrated here and in previous work by our group, gene expression (GEP-R) <ref type="bibr" target="#b37">[35]</ref> or RNA-sequencing based reporting tools constitute convenient methods for such analyses.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Association between antigen expression and specific t-cell responses</head><p><s>T-cell responses in absence of expression of the respective target on malignant plasma cells seem strange at first sight.</s><s>However, it is unlikely that this is due to lack of sensitivity regarding detection.</s><s>First, we had previously shown immune response against CTAs to be detectable despite absence of antigen expression in malignant plasma cells by quantitative real-time PCR <ref type="bibr" target="#b1">[2]</ref>.</s><s>We confirm this here using a different method (GEP) and the additional www.impactjournals.com/oncotarget</s><s>Using the Jonckheere-Terpstra trend-test, a significant trend (P &lt; .001)</s><s>can be found in all comparisons.</s><s>Significant differences between groups (Wilcoxon rank-sum test) are depicted by one asterisk (*) for a level of P &lt; 0.05, two asterisks (**) for a level of P &lt; 0.01, and three (***) for P &lt; 0.001.</s><s>As HMMR is part of the Rs-score, no statistical test was performed in this case.</s></p><p><s>antigens HMMR and WT-1.</s><s>In the latter, responses where exclusively detected with concomitant absent expression, validated with RNA-sequencing in exemplary patients from this cohort, indeed showing no respective reads e.g.</s><s>patient 4 for WT-1 despite T-cell activation.</s><s>However, T-cell activation does not imply actual lysis of myeloma cells which prerequisites expression of the respective target antigen, as it detects the presence of a population of respective responsive T-cells only.</s><s>Generation of reactive T-cells thus could have been against another -likely minor-population of (myeloma) cells present at a site different from the one from which the random aspirate for molecular analysis was drawn (spatial heterogeneity <ref type="bibr" target="#b42">[40]</ref>), or represent cross reactivity between antigens (as e.g. for MART1/HM1.24)</s><s><ref type="bibr" target="#b43">[41]</ref>.</s></p><p><s>Lack of T-cell responses despite target expression is less difficult to understand as one of the most prominent effects of accumulation of malignant plasma cells in myeloma is induction of immunosuppression visible in dysfunctional DCs and diminished T-cell activation <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref>.</s><s>Potential circumvention of this effect is augmenting immune response by adding immunomodulatory drugs like IMiDs <ref type="bibr" target="#b44">[42,</ref><ref type="bibr" target="#b45">43]</ref>, or using vaccination approaches at earlier stages e.g.</s><s>asymptomatic myeloma or MGUS <ref type="bibr" target="#b1">[2]</ref>.</s><s>One of the remaining caveats (and limitation of our study) only www.impactjournals.com/oncotarget</s><s>answerable in a clinical vaccination trial is whether T-cell activation indeed transmits into lysis of myeloma cells expressing the respective antigen.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MATERIALS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients, healthy donors, and samples</head><p><s>Patients with newly diagnosed symptomatic myeloma (n = 458 with available GEP data, see below) according to CRAB criteria <ref type="bibr" target="#b46">[44]</ref> and healthy donors (n = 20) were included in the study approved by the ethics committee (#229/2003, #S-152/2010) after written informed consent.</s><s>Patients were treated in the prospective, randomized, open-label GMMG-MM5 phase III trial (EudraCT no.</s><s>2010-019173-16) <ref type="bibr" target="#b47">[45]</ref>.</s><s>The study is performed in accordance with the Declaration of Helsinki, the European Clinical Trial Directive and was approved by the local ethics committees of all participating institutions.</s><s>See Supplementary Table <ref type="table">S3</ref> for patient characteristics.</s></p><p><s>The prognostic impact of CTA-expression was assessed on an independent cohort of 247 newly diagnosed, therapy-requiring patients treated with highdose chemotherapy followed by autologous stem cell transplantation as published previously <ref type="bibr" target="#b48">[46]</ref>.</s></p><p><s>Normal bone marrow plasma cells and myeloma cells were purified using anti-CD138 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) as published <ref type="bibr" target="#b48">[46]</ref><ref type="bibr" target="#b49">[47]</ref><ref type="bibr" target="#b50">[48]</ref><ref type="bibr" target="#b51">[49]</ref>.</s><s>The negative fraction after plasma cell purification from n = 72 patients foreseen to be included in the GMMG-MM5 trial (including two screening failures) was frozen and used for the generation of DCs as described below (Supplementary Figure <ref type="figure" target="#fig_5">S3</ref>).</s><s>The myeloma cell lines L363, SK-MM-2, LP-1, RPMI-8226, AMO-1, KMS-18, JIM-3, JJN3, KARPAS-620, KMS-12-BM, ANBL-6, KMS-11, MM1S, NCI-H929, KMS-12-PE, U266, OPM2, MOLP-8, MOLP-2, KMM-1, and EJM were purchased from the German Collection of Microorganisms and Cell Cultures, American Type Cell Culture, or Japan Health Science Research Resources Bank; the HG-lines HG1, HG3-HG9, HG11-HG15 and HG17 were generated in the Myeloma Research Laboratory Heidelberg (Germany), the XG-lines XG1-XG7, XG10-XG14, XG16, XG19-XG24 at INSERM (Montpellier, France) <ref type="bibr" target="#b52">[50]</ref>.</s><s>Peripheral blood CD27 + memory B-cells (n = 9) and polyclonal plasmablasts (n = 9) were generated as published <ref type="bibr" target="#b53">[51,</ref><ref type="bibr" target="#b54">52]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of gene expression</head><p><s>Gene expression profiling was performed using U133 2.0 plus arrays (Affymetrix, Santa Clara, CA, USA) <ref type="bibr" target="#b49">[47]</ref><ref type="bibr" target="#b50">[48]</ref><ref type="bibr" target="#b51">[49]</ref><ref type="bibr" target="#b55">53]</ref>.</s><s>Expression data are deposited in ArrayExpress under the accession numbers E-MTAB-2299, E-MTAB-317, E-TABM-937, and E-TABM-1088.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RNA-sequencing</head><p><s>Full-length double-stranded cDNA was generated from 5 ng of total RNA and amplified using the SMARTer Ultra Low RNA Kit (Illumina, San Diego, CA, USA).</s><s>Library preparation was performed from 10 ng of fragmented cDNA using the NEBNext Chip-Seq Library Prep protocol (New England BioLabs, Frankfurt am Main, Germany).</s><s>Libraries were sequenced on an Illumina Hiseq2000 with 2 × 50-bp paired-end reads (n = 152).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HLA typing</head><p><s>Cryopreserved cells were thawed and tested for the presence of HLA-A2 by flow cytometry using anti-human HLA-A2 antibody labeled with fluorescein isothiocyanate (FITC) (BB7.2, mouse IgG2b (κ)) (Biolegend, Fell, Germany).</s><s>Flow cytometry was performed using a LSRII flow cytometer (BD Biosciences, Heidelberg, Germany) and analysis was done with FACSDiva Version 6.1.2</s><s>(BD Biosciences).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Peptides</head><p><s>All HLA-A2-restricted CTA-derived peptides (for sequences see Table <ref type="table">3</ref>) were synthesized at our institution.</s><s>SEB (staphylococcal enterotoxin B, Sigma-Aldrich, Darmstadt, Germany) and the HLA-A2 restricted CMV-pp65 epitope were used as positive controls.</s><s>The HLA-A2 restricted HIV gag SL9 epitope and/or the no-peptidecontrol were used as negative control.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Generation of dendritic cells</head><p><s>Generation of DCs from HLA-A2 + patients was performed as described previously <ref type="bibr" target="#b56">[54]</ref>.</s><s>In brief, HLA-A2 positive tested patient cells were seeded at a density of 4 × 10 4 /well in a 6-well-plate in complete medium consisting of RPMI-1640 with 10% fetal bovine serum (FBS; both Thermo Fisher Scientific, Braunschweig, Germany) and cultured for 2 h at 37°C, and 5% CO 2 to allow an enrichment of monocytes by plastic adherence.</s><s>After aspirating the supernatant and washing twice with phosphate buffered saline (Sigma-Aldrich) the differentiation medium consisting of RPMI-1640 with 10% FBS, 500 U/ml interleukin-4 (IL-4, PeproTech, Hamburg, Germany) and 500 U/ml granulocyte macrophage colony-stimulating factor (GM-CSF, PeproTech) was added.</s><s>After five days of culture the medium was completely changed and replaced by maturation medium containing a pro-inflammatory cytokine cocktail (RPMI-1640, 10% FBS supplemented with 1 µg/ml prostaglandin E [Sigma-Aldrich], 50 ng/ ml tumor necrosis factor alpha [TNFα, Miltenyi Biotec], 10 ng/ml interleukin-6 [IL-6, PeproTech], and 10 ng/ml interleukin-1 β [Miltenyi Biotec]).</s><s>Mature non-adherent www.impactjournals.com/oncotarget</s><s>DCs were harvested after two additional days of culturing and used as antigen presenting cells (APCs).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mixed lymphocyte peptide culture (MLPC)</head><p><s>The moDCs were pulsed for two hours with either a CTA-derived peptide or a control peptide at a concentration of 10 µg/ml.</s><s>CD8+ T lymphocytes were selected from bone marrow mononuclear cells by magnetic-activated cell-sorting (Miltenyi Biotec).</s><s>Following co-incubation of both at a ratio of 5:1 (moDc:CD8 + ; in 96-well plate 2 × 10 4 moDc : 1 × 10 5 CD8 + ) in complete medium, the culture was supplemented with 10 U/ml IL-2 and 20 ng/ml IL-7 (both from PeproTech) on day +1.</s><s>On day seven cells were washed once with medium and subsequently used for interferon-γ (IFNγ) ELISPOT (Enzyme Linked Immuno Spot) assays (see below).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Interferon-γ ELISPOT assay</head><p><s>IFNγ ELISPOT assays were performed as described earlier <ref type="bibr" target="#b33">[31,</ref><ref type="bibr" target="#b34">32,</ref><ref type="bibr" target="#b57">55]</ref>.</s><s>In brief, 96-well hydrophobic IP Multiscreen Filter Plates (Merck Millipore, Darmstadt, Germany) were activated with 35% ethanol and coated with anti-human IFNγ antibody (Mabtech, Nacka Strand, Sweden) overnight at 4°C.</s><s>The next day plates were washed with phosphate buffered saline and blocked with 10% FBS for 2 h at room temperature.</s><s>Presensitized CD8 + cells (effector cells) from MLPC day seven were co-incubated with peptide pulsed T2 cells at a ratio of 1:1 in triplicates (5 × 10 4 effectors per well) for 20 h.</s><s>The secretion of IFNγ was detected using biotinylated anti-human IFNγ antibody (Mabtech), Streptavidin HRP and HRP substrate set (BD Biosciences) according to the manufacturer's instructions.</s><s>The spot forming units (SFU) were counted and analyzed using a CTL-ImmunoSpot ® analyzer equipped with the ImmunoSpot 5.0.9 software (CTL, Bonn, Germany).</s></p><p><s>A specific T-cell response against the respective antigen was defined as ≥ 2-fold increased number of positive ELIspots compared to control, a strong response was defined as ≥ 3-fold increased number of positive ELIspots compared to control.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RNA-sequencing</head><p><s>Next generation sequencing RNA fastq-files were aligned with STAR aligner <ref type="bibr" target="#b58">[56]</ref> to the GRCh38 reference genome (http://www.ensembl.org/Homo_</s><s>sapiens/Info/Index).</s><s>Reads were counted with the summarizeOverlaps function from the Bioconductor package GenomicAlignments <ref type="bibr" target="#b59">[57]</ref>.</s><s>This function was used without quality filtering, as most CTAG1A, -B, and CTAG2 reads mapped to multiple positions due to high sequence homology.</s><s>Technical replicates were summed and subsequently normalized with the counts-permillion function of edgeR <ref type="bibr" target="#b60">[58]</ref>.</s><s>For depicting a gene as "expressed" in RNA-sequencing, a conservative threshold of &gt; 1 normalized read count was used.</s><s>This corresponds to 22.7 ±-13.3 reads supporting the expression of the respective gene.</s><s>The percentage of patients fulfilling this criterion can be interpreted as lower limit of the percentage</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Gene expression profiling</head><p><s>Microarray gene expression analyses were performed on GC-RMA <ref type="bibr" target="#b61">[59]</ref> preprocessed data sets of the B-cell lineage.</s><s>To assess the presence or absence of gene expression the "Presence-Absence calls with negative Probesets" algorithm (PANP) was used <ref type="bibr" target="#b62">[60]</ref>.</s></p><p><s>Gene expression-based assessment of risk (UAMS70-gene score <ref type="bibr" target="#b63">[61]</ref>, Rs-score <ref type="bibr" target="#b39">[37]</ref>, and MYC activation index (MAI) <ref type="bibr" target="#b64">[62]</ref>) and proliferation <ref type="bibr" target="#b55">[53]</ref> were performed as previously published.</s><s>For calculation of the UAMS70-gene score and MAI, the cohort was normalized with the mas5 algorithm.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Survival and further analyses</head><p><s>Event-free and overall survival were assessed using the Kaplan-Meier method <ref type="bibr" target="#b65">[63]</ref>.</s><s>Differences between curves were tested with Log-Rank test.</s><s>HMMR expression is grouped into "low" and "high" expression using maximally selected rank statistics for event-free and overall survival using as cut-off the mean of the individual cut-offs for event-free and overall survival.</s><s>The PANP-algorithm is used to group NY-ESO-1 and MAGE-A3 expression in "present" vs. "absent" (see above).</s><s>Differences in gene expression between defined groups were investigated by Wilcoxon rank sum test.</s></p><p><s>Pearson's correlation coefficient was calculated for comparison of microarray and RNA-seq gene expression.</s></p><p><s>The mean correlation coefficient was calculated using the Fisher-Z transformation transforming correlation coefficients, calculating the mean and subsequent backtransforming.</s></p><p><s>Statistical computations were performed using R <ref type="bibr" target="#b66">[64]</ref>, version 3.2.4 and Bioconductor, version 3.1 <ref type="bibr" target="#b67">[65]</ref>.</s><s>Effects were considered statistically significant if the P-value of corresponding statistical tests was below 5%.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSIONS</head><p><s>T-cell responses can -despite described immunosuppression-be raised frequently within the study population of our GMMG-MM5 trial, and vaccination approaches thus represent a therapeutic option.</s><s>Expression of individual CTAs in a subfraction of patients only, and in turn generation of T-cell responses in an even smaller subfraction of these suggest simultaneous use of a cocktail of peptide vaccines.</s><s>HM1.24, HMMR, MAGE-A3 and NY-ESO-1/2 are good candidates; the latter three associated with adverse prognosis.</s><s>Secondly, it implies that CTA-expression in individual patients needs to be assessed in clinical vaccination trials.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 :</head><label>1</label><figDesc><div><p><s>Figure 1: Expression of HM1.24 and cancer testis antigens in normal and malignant plasma cells as well as cells of the B-cell lineage.</s><s>Shown is the expression of (A) HM1.24, (B) HMMR, (C) MAGE-A3, (D) NY-ESO-1/2, and (E) WT-1 in normal plasma</s></p></div></figDesc><graphic coords="5,89.65,50.39,436.56,182.88" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 :</head><label>2</label><figDesc><div><p><s>Figure 2: IFNγ-secretion of CTA-specific CD8 + T-cells from the bone marrow of patients with multiple myeloma.</s><s>Cells from myeloma patients were used in a MLPC with DCs as APC.</s><s>In ELISPOT assay T2 cells served as APCs.</s><s>In ELISPOTs, 5 × 10 4 cells/ well were seeded and analyses performed in triplicates.</s><s>As negative control (-ctrl) no peptide or an irrelevant HIV-1 peptide was used.</s><s>For positive control (+ctrl) SEB or CMVpp65 peptide were used.</s><s>Dashed lines mark the background.</s><s>Positive is 2 × SFU, strong positive 3 × SFU more than the negative control.</s><s>(A) and (B) display exemplary results from 2/26 patients.</s></p></div></figDesc><graphic coords="6,57.38,274.98,498.24,360.00" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 :</head><label>3</label><figDesc><div><p><s>Figure 3: Expression of CTAs and survival in patients treated with high-dose therapy and autologous stem cell transplantation (n = 247).</s><s>Depicted are event-free (EFS) and overall survival (OS) for (A) HMMR, (B) MAGE-A3, and (C) NY-ESO1/2.</s><s>HMMR expression is grouped into "low" and "high" expression using maximally selected rank statistics for EFS and OS using the mean of the individual cut-offs for EFS and OS as cut-off.</s><s>The PANP-algorithm is used to group MAGE-A3 and NY-ESO-1/2 expression in "present", i.e. expressed, vs. "absent", i.e. not expressed.</s></p></div></figDesc><graphic coords="7,101.92,466.08,419.18,189.32" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 :</head><label>4</label><figDesc><div><p><s>Figure 4: Correlation of CTA expression with tumor mass and molecular characteristics.</s><s>Shown is the correlation of CTA expression for (A) HM1.24, (B) HMMR, (C) MAGE-A3, (D) NY-ESO-1/2, and (E) WT-1 with tumor mass (i.e.</s><s>ISS stage [1 vs. 2 vs. 3]), proliferation (i.e. gene expression-based proliferation index, GPI [GPI low vs. GPI medium vs. GPI high ]) and gene expression-based risk scores (i.e.</s><s>UAMS70-gene score [low vs. high risk], Rs-score [low vs. medium vs. high risk], MYC activation index (MAI) [&lt; 1 vs. ≥ 1]), as well as high-risk chromosomal aberrations according to interphase fluorescence in situ hybridization (i.e.</s><s>presence of deletion 17p13, t(4;14), or gain 1q21), respectively.</s><s>Significant differences between groups (Wilcoxon rank-sum test) are depicted by one asterisk (*) for a level of P &lt; 0.05, two asterisks (**) for a level of P &lt; 0.01, and three (***) for P &lt; 0.001.</s><s>As HMMR is part of the Rs-score, no statistical test was performed in this case.</s></p></div></figDesc><graphic coords="9,106.36,433.94,398.88,192.24" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 5 :</head><label>5</label><figDesc><div><p><s>Figure 5: Association of the number of CTAs and risk-/proliferation-scores.</s><s>The number of the survival relevant CTAs HMMR, MAGE-A3, and NY-ESO-1/2 (depicted on the x-axis) is significantly associated with gene expression-based risk-scores and proliferation (GPI) as shown for (A) GPI, (B) UAMS70-gene score, (C) Rs-score, and (D) MYC activation index (MAI).Using the Jonckheere-Terpstra trend-test, a significant trend (P &lt; .001)</s><s>can be found in all comparisons.</s><s>Significant differences between groups (Wilcoxon rank-sum test) are depicted by one asterisk (*) for a level of P &lt; 0.05, two asterisks (**) for a level of P &lt; 0.01, and three (***) for P &lt; 0.001.</s><s>As HMMR is part of the Rs-score, no statistical test was performed in this case.</s></p></div></figDesc><graphic coords="10,182.78,254.96,247.44,392.16" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Table 3 :</head><label>3</label><figDesc><div><p><s>Sequences of the HLA-A2-restriced CTA-specific peptides sequence and the amino acid positions of the used peptides, respectively.</s><s>*CMV-pp65 served as a positive control.</s><s>HMMR3 and HMMR1-8 are two different RHAMM/HMMR-derived T-cell epitope peptides as defined by others and us<ref type="bibr" target="#b34">[32,</ref><ref type="bibr" target="#b68">66]</ref>.</s><s>** HIV gag served as a negative control.</s><s>We have previously shown the immunogenic oligo-peptide HM1.24aa22-30 (LLLGIGILV) as HLA-A2 restricted T-cell epitope (20) as well as cross-reactivity of HM1.24aa22-30 (LLLGIGILV) with the Melan-A/MART-1 derived peptide Melan-Aaa26-35*A27L (ELAGIGILTV)<ref type="bibr" target="#b22">(21)</ref>, indicated by their sequence conformity at the central peptide position (GIGIL).of</s><s>patients expressing the respective gene.</s><s>Expression profiles of 152 symptomatic multiple myeloma patients, 19 myeloma cell lines, 10 normal bone marrow plasma cell, 4 B-memory cell, and 4 polyclonal plasmablastic cell samples were analyzed.</s><s>Expression values are depicted as ln (normalized counts +1).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="4,118.37,50.56,376.27,330.19" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="4,117.74,395.28,377.52,329.52" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="8,75.10,275.62,462.79,449.06" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 ,</head><label>1</label><figDesc><div><p><s>Supplementary Figure</s></p></div></figDesc><table><row><cell>is expressed in all 458 CD138-purified plasma</cell></row><row><cell>cell samples with available gene expression data. HMMR</cell></row><row><cell>is expressed in 318/458 (69.4%) [91.4%] of samples,</cell></row><row><cell>MAGE-A3 in 209/458 (45.6%) [46.7%], NY-ESO-1/2</cell></row><row><cell>(NY-ESO1 (CTAG1A, CTAG1B), NY-ESO2 (CTAG2)) in</cell></row><row><cell>40/458 (8.7%) [7.2%], and WT-1 in 4/458 (0.8%) [1.9%]</cell></row><row><cell>(Figure 1,</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 : Expression of HM1.24 and CTAs as well as CTA-specific immune responses Patient HM1.24 HMMR-R3 HMMR1-8 HMMR MAGEA3 NY-ESO-1 WT-1</head><label>1</label><figDesc></figDesc><table><row><cell>#</cell><cell cols="2">response GEP</cell><cell>RNA-seq</cell><cell>response</cell><cell>response</cell><cell>GEP</cell><cell>RNA-seq</cell><cell cols="2">response GEP</cell><cell>RNA-seq</cell><cell cols="2">response GEP</cell><cell>RNA-seq</cell><cell cols="2">response GEP</cell><cell>RNA-seq</cell></row><row><cell>1</cell><cell>-</cell><cell>p</cell><cell>-</cell><cell>n</cell><cell>-</cell><cell>a</cell><cell>-</cell><cell>-</cell><cell>p</cell><cell>-</cell><cell>-</cell><cell>a</cell><cell>-</cell><cell>-</cell><cell>a</cell><cell>-</cell></row><row><cell>2</cell><cell>++</cell><cell>p</cell><cell>277.56</cell><cell>++</cell><cell>+</cell><cell>p</cell><cell>6.79</cell><cell>n</cell><cell>p</cell><cell>0.07</cell><cell>n</cell><cell>a</cell><cell>0</cell><cell>n</cell><cell>a</cell><cell>0.07</cell></row><row><cell>3</cell><cell>-</cell><cell>p</cell><cell>306.18</cell><cell>n</cell><cell>-</cell><cell>p</cell><cell>19.47</cell><cell>-</cell><cell>p</cell><cell>1.42</cell><cell>-</cell><cell>a</cell><cell>0</cell><cell>-</cell><cell>a</cell><cell>17.57</cell></row><row><cell>4</cell><cell>++</cell><cell>p</cell><cell>337.21</cell><cell>++</cell><cell>++</cell><cell>p</cell><cell>4.91</cell><cell>n</cell><cell>a</cell><cell>1.41</cell><cell>n</cell><cell>a</cell><cell>0</cell><cell>++</cell><cell>a</cell><cell>0</cell></row><row><cell>5</cell><cell>++</cell><cell>p</cell><cell>-</cell><cell>n</cell><cell>++</cell><cell>a</cell><cell>-</cell><cell>-</cell><cell>a</cell><cell>-</cell><cell>n</cell><cell>a</cell><cell>-</cell><cell>n</cell><cell>a</cell><cell>-</cell></row><row><cell>6</cell><cell>-</cell><cell>p</cell><cell>-</cell><cell>+</cell><cell>-</cell><cell>p</cell><cell>-</cell><cell>-</cell><cell>p</cell><cell>-</cell><cell>-</cell><cell>a</cell><cell>-</cell><cell>-</cell><cell>a</cell><cell>-</cell></row><row><cell>7</cell><cell>n</cell><cell>p</cell><cell>-</cell><cell>n</cell><cell>n</cell><cell>a</cell><cell>-</cell><cell>-</cell><cell>a</cell><cell>-</cell><cell>-</cell><cell>a</cell><cell>-</cell><cell>n</cell><cell>a</cell><cell>-</cell></row><row><cell>8</cell><cell>-</cell><cell>p</cell><cell>-</cell><cell>n</cell><cell>-</cell><cell>a</cell><cell>-</cell><cell>-</cell><cell>p</cell><cell>-</cell><cell>-</cell><cell>a</cell><cell>-</cell><cell>-</cell><cell>a</cell><cell>-</cell></row><row><cell>9</cell><cell>++</cell><cell>p</cell><cell>-</cell><cell>n</cell><cell>n</cell><cell>a</cell><cell>-</cell><cell>n</cell><cell>a</cell><cell>-</cell><cell>+</cell><cell>a</cell><cell>-</cell><cell>+</cell><cell>a</cell><cell>-</cell></row><row><cell>10</cell><cell>-</cell><cell>p</cell><cell>422.29</cell><cell>n</cell><cell>n</cell><cell>p</cell><cell>10.68</cell><cell>-</cell><cell>p</cell><cell>0.48</cell><cell>-</cell><cell>a</cell><cell>0</cell><cell>-</cell><cell>a</cell><cell>0</cell></row><row><cell>11</cell><cell>+</cell><cell>p</cell><cell>-</cell><cell>n</cell><cell>n</cell><cell>a</cell><cell>-</cell><cell>n</cell><cell>p</cell><cell>-</cell><cell>n</cell><cell>a</cell><cell>-</cell><cell>n</cell><cell>a</cell><cell>-</cell></row><row><cell>12</cell><cell>-</cell><cell>p</cell><cell>460.22</cell><cell>n</cell><cell>-</cell><cell>p</cell><cell>3.95</cell><cell>-</cell><cell>p</cell><cell>0.46</cell><cell>-</cell><cell>a</cell><cell>0</cell><cell>-</cell><cell>a</cell><cell>0</cell></row><row><cell>13</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 2 : Overview of the amount of responses to the CTA-specific epitopes</head><label>2</label><figDesc></figDesc><table><row><cell>Antigen</cell><cell>T-cell activation (all) in patients n (%)</cell><cell>T-cell activation (strong) in patients n (%)</cell></row><row><cell>HM1.24</cell><cell>6/12 (50%)</cell><cell>4/12 (33%)</cell></row><row><cell>HMMR-R3</cell><cell>4/26 (15%)</cell><cell>3/26 (11%)</cell></row><row><cell>HMMR1-8</cell><cell>2/14 (14%)</cell><cell>2/14 (14%)</cell></row><row><cell>MAGE-A3</cell><cell>2/8 (25%)</cell><cell>0/8 (0%)</cell></row><row><cell>NY-ESO-1</cell><cell>1/9 (11%)</cell><cell>0/9 (0%)</cell></row><row><cell>WT1</cell><cell>4/11 (36%)</cell><cell>1/11 (9%)</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">www.impactjournals.com/oncotarget</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p><s>The authors thank Tomi Bähr-Ivacevic, Marie-Louise Brygider, Maria Dörner, Mandy Hinkelbein, Doris Lindner, Ewelina Nickel, Véronique Pantesco, and Hendrike Seidt for technical assistance.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICTS OF INTEREST</head><p><s>The authors have no financial conflicts of interest.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GRANT SUPPORT</head><p><s>This work was supported by grants from the German Federal Ministry of Education (BMBF) within the framework of the e:Med research and funding concept "CLIOMMICS" (01ZX1309) and "CAMPSIMM" (01ES1103), and the Deutsche Forschungsgemeinschaft (SFB/TRR79).</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Multiple myeloma</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Kyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Rajkumar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">351</biblScope>
			<biblScope unit="page" from="1860" to="1873" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Association of antigen-specific T-cell responses with antigen expression and immunoparalysis in multiple myeloma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Fichtner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Engelhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Meissner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Neuber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Krasniqi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Raab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schonland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Goldschmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hundemer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="1712" to="1721" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Deregulated cytokine network and defective Th1 immune response in multiple myeloma</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Frassanito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cusmai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Dammacco</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Immunol</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="190" to="197" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pope</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Murray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Esdale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Sze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gibson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Joshua</forename><forename type="middle">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="2992" to="2998" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lonial</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dimopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Palumbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Grosicki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Spicka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Walter-Croneck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Moreau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Mateos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Magen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Belch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Reece</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Beksac</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="621" to="631" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Lokhorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Plesner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Laubach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nahi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gimsing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hansson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Minnema</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Lassen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Krejcik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Palumbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">W</forename><surname>Van De Donk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ahmadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Khan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="1207" to="1219" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><surname>Deckert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Wetzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Bartle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Skaletskaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">S</forename><surname>Goldmacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Vallee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhou-Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ferrari</surname></persName>
		</author>
		<ptr target="www.impactjournals.com/oncotarget" />
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies</title>
		<author>
			<persName><forename type="first">S</forename><surname>Pouzieux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lahoute</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dumontet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Plesa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chiron</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="4574" to="4583" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Carpenter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">O</forename><surname>Evbuomwan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pittaluga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Rose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Raffeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Gress</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">T</forename><surname>Hakim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Kochenderfer</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma</title>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="2048" to="2060" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Rapoport</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Stadtmauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Binder-Scholl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Goloubeva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Vogl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Lacey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Z</forename><surname>Badros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Garfall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Finklestein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kulikovskaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Sinha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kronsberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="914" to="921" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Prospects for gene-engineered T cell immunotherapy for solid cancers</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Klebanoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Restifo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="26" to="36" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Garfall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Maus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Lacey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">D</forename><surname>Mahnke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Melenhorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Vogl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dengel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Nds</forename><surname>Kerr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bagg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="1040" to="1047" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody for the Treatment of Multiple Myeloma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Seckinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Delgado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Moreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Neuber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Grab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lipp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Merino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Vu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Strein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Prosper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hundemer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">San</forename><surname>Miguel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page">117</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Vu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Moser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Delon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Latzko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gianotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lüoend</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Friang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Murr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Duerner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Weinzierl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fauti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bacac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Ast</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page">2998</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Luiten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Kueter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Mooi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Gallee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Rankin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Gerritsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Clift</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Nooijen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Weder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Van De Kasteele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Van Den Berk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">E</forename><surname>Nieweg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="8978" to="8991" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Slingluff</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Petroni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Olson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Czarkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Grosh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Smolkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Chianese-Bullock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename><surname>Neese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Deacon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Nail</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Merrill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fink</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="4973" to="4980" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Tarhini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Leng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Moschos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Gooding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kirkwood</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunother</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="359" to="366" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Induction of HM1.24 peptidespecific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Jalili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ozaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Shibata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hashimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Abe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nishioka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Matsumoto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="3538" to="3545" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Rew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Peggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Sanjuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Pizzey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Koishihara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kawai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kosaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ozaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Yong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="3377" to="3384" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hundemer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Condomines</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lupu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Moos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cremer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kleist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Terness</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Belle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Goldschmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Klein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Hematol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="486" to="496" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103</title>
		<author>
			<persName><forename type="first">A</forename><surname>Moreno-Bost</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Szmania</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Garg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hoerring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Szymonifka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shaughnessy</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Barlogie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Prentice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Van Rhee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cytotherapy</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="618" to="628" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Jungbluth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Diliberto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Niesvizky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Frosina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bhardwaj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chen-Kiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Old</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Cho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="167" to="174" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma</title>
		<author>
			<persName><forename type="first">D</forename><surname>Atanackovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Luetkens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hildebrandt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Arfsten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bartels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Horn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Stahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Zander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bokemeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kroger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1343" to="1352" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Cancer/ testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Condomines</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Raynaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hundemer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Vos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Baudard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Moehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pantesco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Moos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schved</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Reme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Goldschmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of immunology</title>
		<imprint>
			<biblScope unit="volume">178</biblScope>
			<biblScope unit="page" from="3307" to="3315" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">NY-ESO-1 is highly expressed in poorprognosis multiple myeloma and induces spontaneous humoral and cellular immune responses</title>
		<author>
			<persName><forename type="first">F</forename><surname>Van Rhee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Szmania</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pomtree</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Batchu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Moreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Spagnoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shaughnessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Tricot</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="3939" to="3944" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Batchu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Moreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Szmania</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Spagnoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ponnazhagan</surname></persName>
		</author>
		<imprint>
			<pubPlace>Barlogie B, Tricot G, van</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma</title>
		<author>
			<persName><forename type="first">F</forename><surname>Rhee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="10041" to="10049" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Expression of serologically identified tumor www.impactjournals.com/oncotarget antigens in acute leukemias</title>
		<author>
			<persName><forename type="first">P</forename><surname>Niemeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Tureci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Eberle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Graf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pfreundschuh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Sahin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia Res</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="655" to="660" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kurashige</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Noguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Saika</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nagata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jungbluth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ritter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Stockert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tsushima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kumon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Old</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Nakayama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="4671" to="4674" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Expression of the Wilms&apos; tumor gene (WT1) in normal hemopoiesis</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Baird</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Simmons</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Hematol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="312" to="320" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Tissue, developmental, and tumorspecific expression of divergent transcripts in Wilms tumor</title>
		<author>
			<persName><forename type="first">A</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bonetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Mcandrews-Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chilton-Macneill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Coppes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Law</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Feinberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Williams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">250</biblScope>
			<biblScope unit="page" from="991" to="994" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Expression of the Wilms&apos; tumor gene WT1 in solid tumors and its involvement in tumor cell growth</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Oji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ogawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tamaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Oka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tsuboi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Soma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tatekawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kawakami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Asada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kishimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sugiyama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Jpn J Cancer Res</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="194" to="204" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches</title>
		<author>
			<persName><forename type="first">J</forename><surname>Greiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schmitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Giannopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schmitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dohner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Schlenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Pollack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dohner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bullinger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="4109" to="4117" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">J</forename><surname>Greiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ringhoffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Barth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Giannopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Guillaume</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ritter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wiesneth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dohner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schmitt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="938" to="945" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">K</forename><surname>Giannopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bojarska-Junak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rolinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dmoszynska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Hus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Greiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Renner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dohner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schmitt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="95" to="103" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Condomines</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Raynaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hundemer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Vos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baudard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Moehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Pantesco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Moos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Schved</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Rème</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Goldschmidt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">178</biblScope>
			<biblScope unit="page" from="3307" to="3315" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Gene Expression Profiling in Multiple Myeloma-Reporting of Entities, Risk, and Targets in Clinical Routine</title>
		<author>
			<persName><forename type="first">T</forename><surname>Meißner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Seckinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Rème</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hielscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Möhler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Neben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Goldschmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hose</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="7240" to="7247" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Maxwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Keats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Belch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Pilarski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Reiman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="850" to="860" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Modeling risk stratification in human cancer</title>
		<author>
			<persName><forename type="first">T</forename><surname>Reme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Theillet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Klein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1149" to="1157" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation</title>
		<author>
			<persName><forename type="first">D</forename><surname>Atanackovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Arfsten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gnjatic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Schnieders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bartels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schilling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Faltz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wolschke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dierlamm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ritter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Eiermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Hossfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="1103" to="1112" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Dhodapkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Osman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Teruya-Feldstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Filippa</forename><forename type="middle">D</forename><surname>Hedvat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">V</forename><surname>Iversen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kolb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Geller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Hassoun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kewalramani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Comenzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Coplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immun</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">9</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>Expression of cancer/testis</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Dissecting the Clonal Architecture of Multiple Myeloma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Seckinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hose</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Hematology Association</title>
		<imprint>
			<biblScope unit="page" from="173" to="180" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Haematologica)</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24</title>
		<author>
			<persName><forename type="first">O</forename><surname>Christensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lupu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Condomines</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Belle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Maier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Neuber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Moos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kleist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Terness</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Goldschmidt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunother</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="613" to="621" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas</title>
		<author>
			<persName><forename type="first">I</forename><surname>Sakamaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Kwak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Cha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Yi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Surapaneni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bateman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Qin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="329" to="337" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">The anticancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells</title>
		<author>
			<persName><forename type="first">C</forename><surname>Galustian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Labarthe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dredge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Klaschka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Henry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Todryk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Stirling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Schafer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Bartlett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Dalgleish</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immunol Immunother</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="1033" to="1045" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group</title>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="749" to="757" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Mai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Bertsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Durig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kunz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Haenel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">W</forename><surname>Blau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Munder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jauch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schurich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hielscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Merz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Huegle-Doerr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Seckinger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1721" to="1729" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Clinical and prognostic role of annexin A2 in multiple myeloma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Seckinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Meißner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moreaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Depeweg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hillengass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Reme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rosen-Wolff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jauch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schnettler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Ewerbeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Goldschmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Klein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="1087" to="1094" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">impactjournals.com/oncotarget Induction of angiogenesis by normal and malignant plasma cells</title>
		<author>
			<persName><forename type="first">D</forename><surname>Hose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moreaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Meissner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Seckinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Goldschmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Benner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mahtouk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hillengass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Rème</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Vos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hundemer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Condomines</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Bertsch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="128" to="143" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma</title>
		<author>
			<persName><forename type="first">D</forename><surname>Hose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Rème</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Meissner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moreaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Seckinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Benes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Benner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hundemer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hielscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Shaughnessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Barlogie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Neben</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="4331" to="4340" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Seckinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Meissner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moreaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Goldschmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Fuhler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Benner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hundemer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Rème</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Shaughnessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Barlogie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Bertsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hillengass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Ho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="3866" to="3879" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">G</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Gaillard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Robillard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Y</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">J</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jourdan</forename><forename type="middle">M</forename><surname>Boiron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bataille</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="3654" to="3663" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature</title>
		<author>
			<persName><forename type="first">J</forename><surname>Moreaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Cremer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Reme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Raab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mahtouk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kaukel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Pantesco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Vos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jourdan</forename><forename type="middle">E</forename><surname>Jauch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Legouffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Moos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fiol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="1021" to="1030" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization</title>
		<author>
			<persName><forename type="first">M</forename><surname>Jourdan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Caraux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Vos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Fiol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Larroque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cognot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Duperray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Klein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="5173" to="5181" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma</title>
		<author>
			<persName><forename type="first">D</forename><surname>Hose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Reme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hielscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moreaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Meissner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Seckinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Benner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Shaughnessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Barlogie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hillengass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Bertsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Neben</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="87" to="95" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Modification of antigenencoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells</title>
		<author>
			<persName><forename type="first">S</forename><surname>Holtkamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kreiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Selmi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Koslowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Huber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Tureci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Sahin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="4009" to="4017" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schmitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schmitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Rojewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Giannopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Heyduk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ritter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Speiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gnjatic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Guillaume</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="1357" to="1365" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">STAR: ultrafast universal RNA-seq aligner</title>
		<author>
			<persName><forename type="first">A</forename><surname>Dobin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Schlesinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Drenkow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zaleski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Batut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chaisson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Gingeras</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="15" to="21" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Software for computing and annotating genomic ranges</title>
		<author>
			<persName><forename type="first">M</forename><surname>Lawrence</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Huber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Pages</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Aboyoun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Carlson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gentleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Carey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Comput Biol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">e1003118</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Mccarthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Smyth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="139" to="140" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">A Model-Based Background Adjustment for Oligonucleotide Expression Arrays</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Irizarry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gentleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Martinez-Murillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Spencer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Stat Assoc</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="909" to="917" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">PANP -a New Method of Gene Detection on Oligonucleotide Expression Arrays</title>
		<author>
			<persName><forename type="first">P</forename><surname>Warren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pgv</forename><surname>Martini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jackson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bienkowska</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Proceedings of the 7th IEEE International Conference on Bioinformatics and Bioengineering</title>
				<meeting>the 7th IEEE International Conference on Bioinformatics and Bioengineering</meeting>
		<imprint>
			<date type="published" when="2007">2007</date>
			<biblScope unit="page" from="108" to="115" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Shaughnessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Burington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Colla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Hanamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kordsmeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Randolph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Epstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="2276" to="2284" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Chng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Gonzalez-Paz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Troska-Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mulligan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Bergsagel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fonseca</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1026" to="1035" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Nonparametric estimation of the survival distribution in censored data</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Fleming</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Harrington</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Comm in Stat Theory and Methods</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="2469" to="2486" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<monogr>
		<title level="m" type="main">R: A Language and Environment for Statistical Computing</title>
		<author>
			<persName><forename type="first">R</forename><surname>Development Core</surname></persName>
		</author>
		<author>
			<persName><surname>Team</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Bioconductor: open software development for computational biology and bioinformatics</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Gentleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Carey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Bates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bolstad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dettling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dudoit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gautier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gentry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hornik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hothorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Huber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genome Biol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">R80</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo</title>
		<author>
			<persName><forename type="first">S</forename><surname>Spranger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jeremias</forename><forename type="middle">I</forename><surname>Wilde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Leisegang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Starck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mosetter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Uckert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Heemskerk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Schendel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Frankenberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="3440" to="3449" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
